Ipsen faces another setback for bone disorder drug with EMA panel rejection

European Union flags against parliament in Brussels

art Jazz

A committee of the European Medicines Agency (EMA) rejected the Ipsen’s recommendation (OTCPK: IPSEY) (OTCPK:IPSEF) the drug palovarotene is approved in the EU for the treatment of a rare bone disorder.

The EMA’s Committee on Medicines for Human Use (CHMP) has recommended not to authorize marketing


News7F: Update the world's latest breaking news online of the day, breaking news, politics, society today, international mainstream news .Updated news 24/7: Entertainment, the World everyday world. Hot news, images, video clips that are updated quickly and reliably

Related Articles

Back to top button